|
|
|
11-50 employees
View all
|
|
Pharmaceuticals
|
|
Suite 400,Mississauga,Ontario,CA
|
|
YM BioSciences Inc. is a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.
YM BioSciences is currently advancing three late-stage products:
•CYT387: JAK 1/2 small molecule inhibitor initially targeting the treatment of a group of hematological disorders known as myeloproliferative neoplasms (MPNs), also known as myeloproliferative disorders.
•Nimotuzumab: EGFR-targeting Affinity-Optimized Antibody™ in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation; approved for marketing in 25 countries.
•CYT997: novel anti-cancer Vascular Disrupting Agent (VDA) in Phase II clinical development for the treatment of a variety of tumors.
|
YM BioSciences Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
100%
|
The widely used YM BioSciences email format is {f}{last} (e.g. [email protected]) with 100% adoption across the company.
To contact YM BioSciences customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.